Abstract: Objective To investigate the incidence of BRAF mutation and its relationships with clinicopathological characteristics in patients with PTC. Methods 253 patients with papillary thyroid carcinoma who underwent surgery in the department of thyroid and breast surgery of the First People′s Hospital of Lianyungang from January 2018 to December 2019 were selected. The relation between the mutation of BRAF and clinicopathological features of papillary thyroid carcinoma patients was analyzed. Results The BRAF mutation was present in 81% of patients （205 of 253）. The frequency of BRAF mutation increased with age. There were significant correlations between BRAF mutation and lymph node metastasis, and between BRAF mutation and the clinical stage of papillary thyroid cancer （P<0.05）. Multivariate Logistic regression analysis showed that ≥45 years older, high clinical stage and lymph node metastasis were independent factors for BRAF mutation. Conclusion The mutation of BRAF is associated with the lymph node metastasis, and clinical stage of PTC, and may have a positive predictive value for diagnosing thyroid tumors.

Key words: papillary thyroid carcinoma, BRAF, mutation, clinicopathological feature

摘要： 目的 探讨BRAF基因在甲状腺乳头状癌（PTC）中的突变率,及其与临床病理学特征的关系。方法 选取2018年1月至2019年12月经手术治疗的253例甲状腺乳头状癌患者作为研究对象,分析BRAF基因突变与甲状腺乳头状癌患者临床病理学特征的关系。结果 81%的PTC患者中发现有BRAF基因的突变。BRAF突变率随着年龄的增长而增加,BRAF 突变与PTC的淋巴转移以及临床分期间比较,差异有统计学意义（P<0.05）。多因素Logistic回归分析显示年龄≥45岁、高肿瘤分期、区域淋巴结转移是BRAF突变的独立影响因素（均P<0.05）。结论 BRAF基因突变与PTC淋巴结转移、临床分期相关,而且对于甲状腺肿瘤良恶性的诊断具有重要价值。

关键词: 甲状腺乳头状癌, BRAF, 突变, 临床病理性特征